critical
Trial status changed: Recruiting → Withheld
2026-05-07
critical
Phase changed: not applicable -> not specified
2026-05-07
critical
Primary endpoint(s) modified
2026-05-07
notable
Enrollment changed: 125 -> None
2026-05-07
notable
Sponsor changed: Galderma R&D -> [Redacted]
2026-05-07
minor
Trial arms changed: 2 -> 0
2026-05-07
notable
Trial sites reduced: 6 -> 0 locations
2026-05-07